| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.21 | 3e-05 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.21 | 6e-05 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.25 | 0.0005 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.17 | 0.0005 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.001 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.17 | 0.003 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.003 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.16 | 0.003 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |